Quick Takeaways
- Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G/A for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO).
- Disclosed ownership: 6.7%.
- Date of event: 31 Dec 2025.
Frazier Life Sciences Public Fund, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO)
- Filing Manager
- Frazier Life Sciences Public Fund, L.P.
- Reporting Manager
- Frazier Life Sciences Public Fund, L.P.
- Symbol
- XLO
- Shares outstanding
- 69,798,090 shares
- Disclosed Ownership
- 4,676,472 shares
- Ownership
- 6.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2026, 17:31:59 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Frazier Life Sciences Public Fund, L.P. disclosed 6.7% ownership in Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 13 Feb 2026, 17:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (14)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 6.7% | 4,676,472 | 0 | 4,676,472 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P. | |
| FHMLSP, L.P. | 6.7% | 4,676,472 | 0 | 4,676,472 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P. | |
| FHMLSP, L.L.C. | 6.7% | 4,676,472 | 0 | 4,676,472 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLSP, L.L.C. | |
| Frazier Life Sciences X, L.P. | 0.2% | 149,060 | 0 | 149,060 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P. | |
| FHMLS X, L.P. | 0.2% | 149,060 | 0 | 149,060 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P. | |
| FHMLS X, L.L.C. | 0.2% | 149,060 | 0 | 149,060 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS X, L.L.C. | |
| Frazier Life Sciences XI, L.P. | 0.6% | 396,902 | 0 | 396,902 | Jennifer Martin | By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P. | |
| FHMLS XI, L.P. | 0.6% | 396,902 | 0 | 396,902 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P. | |
| FHMLS XI, L.L.C. | 0.6% | 396,902 | 0 | 396,902 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS XI, L.L.C. | |
| Frazier Life Sciences XII, L.P. | 1% | 692,657 | 0 | 692,657 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P. | |
| FHMLS XII, L.P. | 1% | 692,657 | 0 | 692,657 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P. | |
| FHMLS XII, L.L.C. | 1% | 692,657 | 0 | 692,657 | /s/ Jennifer Martin | By Jennifer Martin, General Counsel of FHMLS XII, L.L.C. | |
| James N. Topper | 0.2% | 149,060 | 0 | 149,060 | /s/ Jennifer Martin | By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026 | |
| Patrick J. Heron | 0.2% | 149,060 | 0 | 149,060 | /s/ Jennifer Martin | By Jennifer Martin, Attorney-in-Fact for Patrick Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026 |